• Users Online: 209
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 5  |  Issue : 2  |  Page : 83-88

Real-world experience on the effectiveness and tolerability of apremilast in patients with plaque psoriasis in India

1 Dermocosmetology Laser Center Lilavati Hospital, Mumbai, Maharashtra, India
2 Department of DVL, Sri Balaji Medical College and Hospital, Chennai, Tamil Nadu, India
3 Department of Dermatology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India
4 Medical Services, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Dhiraj Dhoot
B D Sawant Marg, Chakala, Andheri (E), Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdd.ijdd_16_19

Rights and Permissions

Introduction: Apremilast, a phosphodiesterase-4 inhibitor, has been recently approved for the management of plaque psoriasis in India in 2017. However, no real-world experience pertaining to apremilast has been documented. Materials and Methods: A retrospective review of medical records was conducted of all patients across India who were prescribed apremilast for an entire 16 weeks. The primary endpoint was the percentage of patients achieving the Psoriasis Area and Severity Index (PASI) 75 at 16 weeks. The secondary endpoints were as follows: (i) change in mean PASI; (ii) change in mean body surface area (BSA); (iii) percentage of patients who achieved PASI 50, 90, and 100; and (iv) adverse events (AEs) reported. Results: We analyzed the records of 105 patients. Mean age was 41 years and mean disease duration was 6.75 years. All the patients had previously received some forms of systemic treatment. Forty-three patients (41%) achieved ≥ PASI 75 of which four patients (3.8%) and five patients (4.76%) achieved PASI 100 and PASI 90, respectively at week 16. Moreover, 28 patients (26.7%) demonstrated PASI 50 response. Baseline mean PASI score of 14.78 reduced to 4.5 (−69.55%), whereas mean BSA score of 24.4 reduced to 8.24 (−66.3%). Nine patients discontinued apremilast due to adverse effects. Thirty-five patients (33.3%) had one or more AEs, diarrhea being the most common (30.5%) followed by nausea (20.3%). Most AEs were mild to moderate in severity. Conclusion: These results, from a real-world setting in India, confirm the effectiveness and tolerability of apremilast as seen in clinical trials.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded137    
    Comments [Add]    
    Cited by others 1    

Recommend this journal